Hims & Hers Health's EBIT per Share for the
three
months ended in Mar. 2026 was CHF-0.34.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-0.16.
During the past 12 months, the average EBIT per Share Growth Rate of Hims & Hers Health was -135.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Hims & Hers Health's EBIT per Share or its related term are showing as below:
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Hims & Hers Health was 46.10% per year. The lowest was 30.70% per year. And the median was 38.40% per year.
XSWX:HIMS's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.8 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Hims & Hers Health (XSWX:HIMS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Hims & Hers Health EBIT per Share Related Terms
Hims & Hers Health EBIT per Share Historical Data
* Premium members only.
The historical data trend for Hims & Hers Health's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-0.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hims & Hers Health (XSWX:HIMS) has a EBIT per Share of CHF-0.16 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hims & Hers Health and its competitors. According to the industry distribution chart, Hims & Hers Health ranks #999999 out of 811 companies in the Drug Manufacturers industry.
Is Hims & Hers Health's EBIT per Share too high?
Hims & Hers Health's current EBIT per Share is CHF-0.16. Based on the distribution chart, Hims & Hers Health ranks #999999 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hims & Hers Health has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's EBIT per Share compare to ?
According to the Drug Manufacturers industry distribution chart, Hims & Hers Health ranks #999999 out of 811 companies for EBIT per Share. This places Hims & Hers Health in the lower half of its industry. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hims & Hers Health and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hims & Hers Health's current EBIT per Share is CHF-0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Hims & Hers Health (XSWX:HIMS) has a current EBIT per Share of CHF-0.16. The stock's GF Value™ is CHF32.30, compared to a current price of CHF29.90 — trading 7.4% below its estimated fair value. The current EBIT per Share is CHF-0.16. Hims & Hers Health's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Hims & Hers Health (XSWX:HIMS), the current EBIT per Share is CHF-0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hims & Hers Health (XSWX:HIMS) Overvalued in 2026?
Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued.
The current stock price of CHF29.90 is trading 7.4% below its estimated GF Value™ of CHF32.30.
Key valuation signals for XSWX:HIMS:
EBIT per Share: CHF-0.16
GF Value™: CHF32.30 vs. price of CHF29.90 (7.4% below fair value)
No single metric tells the full story. See the XSWX:HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
81GF Score
Get the complete analysis for XSWX:HIMS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:HIMS has been successfully added to your 
